ArticleFrontiers in immunology2025
Clinical characteristics and factors associated with recurrence and long-term prognosis in patients with MOGAD.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Identification of risk factors for relapse at initial onset in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis using ophthalmic findings.Japanese journal of ophthalmology · 2026Article
- Adult Onset of Acute Disseminated Encephalomyelitis (ADEM) With Associated Myelin Oligodendrocyte Glycoprotein (MOG) Antibody.Case reports in immunology · 2026Article
- The relationship between serum MOG-IgG titer status and titers and the prognosis of pediatric MOGAD: a retrospective cohort study.Frontiers in pediatrics · 2026Article
- Neurological graft-versus-host disease with MOG antibody positivity after allogeneic stem cell transplantation: a case report.Frontiers in immunology · 2026Article
- MOGAD: A Shifting Landscape-From Pathogenesis to Personalised Management, Global Perspectives and Latin American Insights.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe the clinical features, treatment, and prognostic factors affecting recurrence and long-term adverse outcomes of myelin oligodendrocyte antibody-associated disease (MOGAD). Methods: In this retrospective cohort study, the records of patients diagnosed with MOGAD at Zhengzhou University First Affiliated Hospital between January 2018 and March 2023 were analyzed, and factors associated with recurrence and poor long-term prognosis were identified using logistic regression. Results: Of the 91 patients, 69 (76%) were new cases, 39 (43%) were female, and 47 (52%) were children (<18 years). Clinical manifestations included optic neuritis (ON) in 13 (14%), transverse myelitis (TM) in 14 (15%), brain disease in 37 (41%), and mixed encephalomyelitis in 27 (30%). The prevalence of acute disseminated encephalomyelitis (ADEM) was significantly higher in children than in adults (43% versus 18%, p = 0.012), whereas the prevalence of TM was significantly higher in adults (30% versus 2%, p < 0.001). Combined steroid and intravenous immunoglobulin (IVIG) treatment during hospitalization was more frequent in children than in adults (36% versus 11%, p = 0.006), and children had a better short-term prognosis than that in adults at discharge (median [interquartile range (IQR)]) Expanded Disability Status Scale [EDSS]: 1 [0-1] versus 2 [0-4.75], p = 0.007; Modified Rankin Score [mRS]: 1 [0-1] versus 1 [0-2], p = 0.006). Visual impairment was a risk factor for recurrence (odds ratio [OR]: 4.22, 95% confidence interval [CI]: 1.24-14.38, p = 0.022). A higher EDSS score at discharge (OR: 5.05, 95% CI: 1.27-20.07, p = 0.021)and more previous episodes (OR: 9.24, 95% CI: 1.35-63.10, p = 0.023), were associated with a poor long-term prognosis; whereas steroid therapy for >5 weeks at first diagnosis (OR: 0.001, 95% CI: 0.00-0.33, p = 0.019) and type I isoelectric focusing pattern (OR: 0.004, 95% CI: 0.00-0.402, p = 0.043) were associated with favorable long-term prognosis. Conclusion: After the first episode, steroid maintenance for an appropriate period following discharge is important for achieving a favorable long-term prognosis, particularly in patients with a high EDSS score at discharge and those at a heightened risk of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.